Jennifer Klauschie, MD
Urogynecology and Reconstructive Pelvic Surgery · Litchfield Park, AZNPI 1083808265
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,600 of the $95,276 with a category attached, or 85.6%. Caldera Medical, Inc accounts for 88.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $81,392 and has fallen 98.8% since, to $989 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $375.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$84K
- Astellas Pharma US Inc$5K
- Medtronic$3K
- Boston Scientific$614
- Sumitomo Pharma America, Inc.$396
- Femselect Inc.$299
- plus $1K from 15 others
Across 4 payments — averaging $4855.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$19K
What the payments were for
- Consulting fees$81,60086%
- Speaking & faculty fees$6,0256%
- Travel & lodging$2320%
- Food & beverage$7,0877%
- Education$1750%
- Gifts$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 86 | $84,064 |
| Astellas Pharma US Inc | 41 | $5,192 |
| Medtronic(2 entities) | 41 | $3,497 |
| Boston Scientific | 20 | $614 |
| Sumitomo Pharma America, Inc. | 15 | $396 |
| Femselect Inc. | 4 | $299 |
| AbbVie(2 entities) | 12 | $248 |
| Bluewind Medical | 2 | $191 |
| Axonics, Inc. | 8 | $181 |
| Urovant Sciences Inc | 8 | $172 |
| Coopersurgical, Inc. | 2 | $141 |
| Coloplast | 5 | $103 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Therapeuticsmd, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $23 |
| Intuitive Surgical | 1 | $22 |
| Blue Earth Diagnostics | 1 | $17 |
| Rochester Medical Corporation | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $10 |
| Valencia Technologies Corporation | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Desara$82,723
- Vertessa$76,317
- MYRBETRIQ$4,388
- INTERSTIM$2,518
- EnPlace$159
- GENERAL FEMALE SUI$158
- GENERAL KIDNEY STONE DISEASE$138
- ONETRAC LX$119
How this compares
$95,276 in reported general payments places this provider in the 95th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.
See all urogynecology and reconstructive pelvic surgery providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 271 | $149,180 |
| GemtesaVibegron | 40 | $32,233 |
| Estradiol | 411 | $24,588 |
| Solifenacin Succinate | 355 | $12,364 |
| Trospium Chloride | 51 | $3,511 |
| Oxybutynin Chloride ErOxybutynin Chloride | 117 | $2,813 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 247 | $1,388 |
| Cephalexin | 109 | $787 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 30 | $627 |
| Oxybutynin Chloride | 14 | $412 |
| Betamethasone Dipropionate | 14 | $404 |
| Ciprofloxacin Hcl | 45 | $309 |
| CefuroximeCefuroxime Axetil | 23 | $208 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $154 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 35 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $5,192 | $149,180271 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $396 | $32,23340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.
Other urogynecology and reconstructive pelvic surgery in Litchfield Park
- Christina RogersLitchfield Park$9K
- Keri WongLitchfield Park$9K
- Hemikaa DevakumarLitchfield Park$4K
- Suzette SutherlandScottsdale$354K
- Gina CliettOro Valley$76K
- Anthony GaddiGilbert$72K
- Felipe VidelaPhoenix$25K
- Kelly KantartzisMesa$21K
- Daniel StonePhoenix$20K
- Mohammad IslamScottsdale$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.